Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Lebwohl, 2016, US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey, Am J Clin Dermatol, 17, 87, 10.1007/s40257-015-0169-x Kragballe, 2014, Unmet needs in the treatment of psoriasis, Eur J Dermatol, 24, 523, 10.1684/ejd.2014.2403 Blome, 2016, Patient-relevant treatment goals in psoriasis, Arch Dermatol Res, 308, 69, 10.1007/s00403-015-1613-8 Strober, 2016, Clinical meaningfulness of complete skin clearance in psoriasis, J Am Acad Dermatol, 75, 77, 10.1016/j.jaad.2016.03.026 Bartos, 2016, Review of maintenance of response to psoriasis treatments, J Dermatolog Treat, 27, 293, 10.1080/09546634.2016.1177158 Gniadecki, 2015, Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris, Br J Dermatol, 172, 244, 10.1111/bjd.13343 Gordon, 2015, A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis, N Engl J Med, 373, 136, 10.1056/NEJMoa1501646 Griffiths, 2015, Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomized trials, Lancet, 386, 541, 10.1016/S0140-6736(15)60125-8 Krueger, 2015, Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial, J Allergy Clin Immunol, 136, 116, 10.1016/j.jaci.2015.01.018 Lebwohl, 2015, Phase 3 studies comparing brodalumab with ustekinumab in psoriasis, N Engl J Med, 373, 1318, 10.1056/NEJMoa1503824 Leonardi, 2012, Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis, N Engl J Med, 366, 1190, 10.1056/NEJMoa1109997 Papp, 2015, Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial, Br J Dermatol, 173, 930, 10.1111/bjd.13932 Sofen, 2014, Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis, J Allergy Clin Immunol, 133, 1032, 10.1016/j.jaci.2014.01.025 Langley, 2014, Secukinumab in plaque psoriasis–results of two phase 3 trials, N Engl J Med, 371, 326, 10.1056/NEJMoa1314258 Blauvelt, 2017, Efficacy and safety of guselkumab, an anti-IL-23 monoclonal antibody, compared with adalimumab for the continuous treatment of moderate-to-severe psoriasis: results from the phase III VOYAGE 1 trial, J Am Acad Dermatol, 76, 405, 10.1016/j.jaad.2016.11.041 Brezinski, 2012, Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy, PLoS One, 7, e33486, 10.1371/journal.pone.0033486 Doshi, 2016, Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population, J Am Acad Dermatol, 74, 1057, 10.1016/j.jaad.2016.01.048 Bonafede, 2013, Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting, J Dermatolog Treat, 24, 369, 10.3109/09546634.2012.755255 Svedbom, 2015, Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis, J Eur Acad Dermatol Venereol, 29, 215, 10.1111/jdv.12494 Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002 Finlay, 1994, Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use, Clin Exp Dermatol, 19, 210, 10.1111/j.1365-2230.1994.tb01167.x Mathias, 2016, Measurement properties of a patient-reported outcome measure assessing psoriasis severity: the psoriasis symptoms and signs diary, J Dermatolog Treat, 27, 322, 10.3109/09546634.2015.1114567 Feldman, 2016, Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: the psoriasis symptoms and signs diary, J Dermatol Dermatol Surg, 20, 19, 10.1016/j.jdds.2015.07.004 Gordon, 2006, Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy, J Dermatolog Treat, 17, 9, 10.1080/09546630500472838 Leonardi, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1), Lancet, 371, 1665, 10.1016/S0140-6736(08)60725-4 Menter, 2007, A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis, J Am Acad Dermatol, 56, 31.e1, 10.1016/j.jaad.2006.07.017 Menter, 2008, Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial, J Am Acad Dermatol, 58, 106, 10.1016/j.jaad.2007.09.010 Brunner, 2013, Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages, J Allergy Clin Immunol, 132, 1184, 10.1016/j.jaci.2013.05.036 Reich, 2015, Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis, Exp Dermatol, 24, 529, 10.1111/exd.12710 Miossec, 2009, Interleukin-17 and type 17 helper T cells, N Engl J Med, 361, 888, 10.1056/NEJMra0707449 Zheng, 2007, Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis, Nature, 445, 648, 10.1038/nature05505